SEC Form 4Coverage since Jun 1, 2026
$SYRE insider trading
Over the last 12 months, Spyre Therapeutics insiders reported no purchases and 15 sales totaling $410.0M across SEC Form 4 filings. 87% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $410.0M 15 events
- Events · 12m
- 15 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 87% pre-arranged plans
Side
Price · $SYRE · 12Mvia TradingView
Top insiders · 12m
Burrows Scott LChief Financial Officer6× · $3.2M
Turtle CameronChief Executive Officer5× · $3.8M
Sloan SheldonChief Medical Officer2× · $1.4M
HENDERSON MICHAEL THOMAS—1× · $2.0M
Fairmount Funds Management LLC—1× · $399.7M
All insider trades
15 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 7,500 | $95.57 | $717K | -7.1% | plan · 3 tranches |
| Aug 3, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $95.51 | $1.4M | -2.6% | plan · 5 tranches |
| Jul 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 7,500 | $87.74 | $658K | -7.1% | plan · 2 tranches |
| Jul 1, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 8,334 | $87.7 | $731K | -100% | plan · 2 tranches |
| Jul 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 15,000 | $87.69 | $1.3M | -2.5% | plan · 3 tranches |
| Jun 25, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 15,000 | $87.13 | $1.3M | -13.3% | 2 tranches |
| Jun 23, 2026 | Fairmount Funds Management LLCD | ▼ Sale | 4,684,781 | $85.31 | $399.7M | -100% | indirect |
| Jun 22, 2026 | HENDERSON MICHAEL THOMASD | ▼ Sale | 20,000 | $100 | $2.0M | -22.6% | plan |
| Jun 3, 2026 | Sloan SheldonChief Medical Officer · O | ▼ Sale | 8,333 | $75 | $625K | -100% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 3,294 | $71.38 | $235K | -0.5% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 8,149 | $70.5 | $575K | -1.3% | plan |
| Jun 1, 2026 | Turtle CameronChief Executive Officer · O·D | ▼ Sale | 3,557 | $69.4 | $247K | -0.6% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 3,100 | $72.06 | $223K | -3.1% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 2,599 | $70.77 | $184K | -2.5% | plan |
| Jun 1, 2026 | Burrows Scott LChief Financial Officer · O | ▼ Sale | 1,801 | $69.75 | $126K | -1.7% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $SYRE feed.